Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1934255-39-6
Drug Levels and Effects
Summary of Use during Lactation
Lonapegsomatropin is a long-acting prodrug of somatropin, which has been used safely in nursing mothers. Polyethylene glycol is not excreted into breastmilk.[3] No special precautions are required.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date. However, somatropin has been reported to increase milk production.
Alternate Drugs to Consider
Substance Identification
Substance Name
Lonapegsomatropin
CAS Registry Number
1934255-39-6
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Lonapegsomatropin: Pediatric First Approval.[Paediatr Drugs. 2022]Review Lonapegsomatropin: Pediatric First Approval.Lamb YN. Paediatr Drugs. 2022 Jan; 24(1):83-90.
- TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation.[Expert Opin Drug Deliv. 2022]TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation.Dos Santos JBR, Da Silva MRR. Expert Opin Drug Deliv. 2022 Jan; 19(1):1-7. Epub 2022 Jan 24.
- Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency.[J Endocr Soc. 2022]Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency.Lin Z, Shu AD, Bach M, Miller BS, Rogol AD. J Endocr Soc. 2022 Jan 1; 6(1):bvab168. Epub 2021 Nov 8.
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.[J Clin Endocrinol Metab. 2021]Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, Song W, Christoffersen ED, Breinholt VM, Kovalenko T, et al. J Clin Endocrinol Metab. 2021 Oct 21; 106(11):3184-3195.
- Review Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.[Drug Des Devel Ther. 2022]Review Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.Miller BS, Yuen KCJ. Drug Des Devel Ther. 2022; 16:2055-2066. Epub 2022 Jun 29.
- Lonapegsomatropin - Drugs and Lactation Database (LactMed®)Lonapegsomatropin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...